focus -WSS

focus

author：explore 2025-09-30 23:07:36 - browse：45272

Sen. Rand Paul (C) (R-KY) questions Homeland Security Secretary Alejandro Mayorkas and FBI Director Christopher Wray during a hearing held by the Senate Homeland Security and Governmental Affairs Committee October 31, 2023 in Washington, DC. — Sen. Rand Paul (R-Ky.) Win McNamee/Getty Images

WASHINGTON — A Senate panel Wednesday passed a bill aimed at preventing certain Chinese companies from doing business in the United States. The sole no vote was by Sen. Rand Paul (R-Ky.), who worries that Congress is using anger toward China as a cover for advancing parochial interests.

Many in Congress are worried the Chinese government and military are using the rising dominance of national companies to gather Americans’ genetic information, which could be used for reasons that range from creating bioweapons to giving China a leg up in drug development.

The Biosecure Act, by Homeland Security and Governmental Affairs Chair Gary Peters (D-Mich.), is a response to those concerns. The bill would block the U.S. government from contracting with companies that do business with Chinese “biotechnology companies of concern,” and it names four companies that must be on that list: BGI Genomics, MGI, Complete Genomics, WuXi AppTec, and any subsidiary, parent affiliate, or successor of these companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Amid AI frenzy, a top HHS official's quest to create safeguards

WSS

Amid AI frenzy, a top HHS official's quest to create safeguards

Tuberculosis patients need more than just free medication

Why depression after traumatic brain injury is distinct

John Green on his newest strategy for fighting tuberculosis

Boston's new lab space is opening empty

Readout Newsletter: CAR

focus

focus

knowledge

Affirmative action in medical school literally saved lives

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Sports medicine is finally prioritizing gender equality

Trump used to be more articulate. What could explain the change?

Walensky prepares to leave CDC — and Congress — behind

Google's generative AI to analyze medical images — and talk to docs

In age of alternative facts, a scholarly course on calling out crap

Change Healthcare outage fallout shows need for new oversight

Cancer drug shortages should be causing more outrage

WuXi out of biotech trade group, U.S. and China relations to blame

Wikipedia

Medicare coverage of Wegovy, once blocked, now looks possible

Sage considers ways to reduce costs following FDA rejection

President Biden's budget: Here's what you might have missed

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Steward Health Care Massachusetts hospitals face fiscal disaster

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

leisure time

leisure time

explore

knowledge